An approach to finding specific forms of dysbiosis that associate with different disorders

Background: Many disorders display dysbiosis of the enteric microbiome, compared with healthy controls. Different disorders share a pattern of dysbiosis that may reflect ‘reverse causation’, due to non-specific effects of illness-in-general. Combining a range of disorders into an ‘aggregate nonhealthy active control’ (ANHAC) group should highlight such non-specific dysbiosis. Differential dysbiosis between the ANHAC group and specific disorders may then reflect effects of treatment or bowel dysfunction, or may potentially be causal. Here, we illustrate this logic by testing if individual genera can differentiate an ANHAC group from two specific diagnostic groups.

Read Prepublication: 2024.04.23.24306162v1.full

Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?

Abstract: Dysmenorrhoea effects up to 90% of women of reproductive age, with medical management options including over-the-counter analgesia or hormonal contraception. There has been a recent surge in medicinal cannabis research and its analgesic properties. This paper aims to critically investigate the current research of medicinal cannabis for pain relief and to discuss its potential application to treat dysmenorrhoea.

Click Here for the full document

Comparing the Results from Faecal Microbiome Transplantation (Fmt) and Gut Flora Replacement Therapy (Gfrt) using 16s Mrna Microbiome Mapping

Corresponding author: Julian N Kenyon, The Dove Clinic, Twyford, Winchester, Hampshire, SO21 1NT, England.

International Journal of Clinical Studies & Medical Case Reports – ISSN 2692-5877


We compared the results from 10 randomly chosen FMT patients and 10 randomly chosen patients using GFRT. We used 16S mRNA microbiome mapping on all of these patients. We identified that GFRT is just as effective as FMT, a great deal safer and is a necessary step to protect patients from catching COVID-19.

We have previously used FMT, this is well researched and there has been significant success in difficult to treat conditions.  With the advent of the pandemic, we had to reconsider our use of donor derived laboratory processed implants because of the potential transmission of COVID-19 from exposure to such implants.

What we also noted is that the now standard use of measurements in sewage water waste by water authorities, measuring the levels of COVID-19 in the sewage effluent has proven to be a reliable indicator of the prevalence of local outbreaks and indeed, this level of COVID-19 in the sewage effluent predates the onset of an outbreak of COVID-19 locally.

Click here for link to full document.

Trypsinogen and chymotrypsinogen: potent anti-tumour agents

,,, &

Received 03 Nov 2020, Accepted 23 Apr 2021, Accepted author version posted online: 24 Apr 2021 


Trypsinogen and chymotrypsinogen have been used clinically in tissue repair due to their ability to resolve inflammatory symptoms. Recently, novel evidence has supported the anti-tumourigenic potential of a mixture of trypsinogen and chymotrypsinogen.

Outcome measures following Sono and Photodynamic Therapy – A Case Series

Julian N. Kenyon

The Dove Clinic, Twyford, Winchester, Hampshire, SO21 1NT, England

Published on: March 30, 2021 – Journal of Cancer Treatment and Diagnosis

Sono and Photodynamic Therapy (SPDT) is a novel therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of photodynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents
a promising development to Photodynamic Therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. This case series of 17 consecutive patients with a variety of cancer diagnoses outlines clinical outcomes over a four-year period
of SPDT. The results have been encouraging in that all cases who carried our Circulating Tumour Cell Tests before and after SPDT showed a significant drop in tumour cells post-SPDT. SPDT is worthy of further investigation as an effective and well tolerated treatment for a wide variety of primary and metastatic tumours, including those refractory to Chemotherapy.

Click here for full text

A Retrospective Outcome Study of 42 Patients with Chronic Fatigue Syndrome, 30 of Whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation


The gut microbiome comprises the community of microorganisms in the intestinal tract. Research suggests that an altered microbiome may play a role in a wide range of disorders including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Click here for full text (external link)

Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting


Cancer stem cells (CSCs) subpopulation within the tumour is responsible for metastasis and cancer relapse. Here we investigate in vitro and in vivo the effects of a pancreatic (pro)enzyme mixture composed of Chymotrypsinogen and Trypsinogen (PRP) on CSCs derived from a human pancreatic cell line, BxPC3. Exposure of pancreatic CSCs spheres to PRP resulted in a significant decrease of ALDEFLUOR and specific pancreatic CSC markers (CD 326, CD 44 and CxCR4) signal tested by flow cytometry, further CSCs markers expression was also analyzed by western and immunofluorescence assays. PRP also inhibits primary and secondary sphere formation. Three RT2 Profiler PCR Arrays were used to study gene expression regulation after PRP treatment and resulted in, (i) epithelial-mesenchymal transition (EMT) inhibition; (ii) CSCs related genes suppression; (iii) enhanced expression of tumour suppressor genes; (iv) downregulation of migration and metastasis genes and (v) regulation of MAP Kinase Signalling Pathway. Finally, in vivo anti-tumor xenograft studies demonstrated high anti-tumour efficacy of PRP against tumours induced by BxPC3 human pancreatic CSCs. PRP impaired engrafting of pancreatic CSC’s tumours in nude mice and displayed an antigrowth effect toward initiated xenografts. We concluded that (pro)enzymes treatment is a valuable strategy to suppress the CSC population in solid pancreatic tumours.

Click here for full text (external link)

Social media & sharing icons powered by UltimatelySocial